Keely Macmillan, MSPH
Advertisement
Articles by Keely Macmillan, MSPH
COVID-19 has delayed the transition to Oncology Care First, but the forthcoming model could help.
Oncology drug costs affect those entering into risk-based arrangements, and these groups must rethink their approach to evaluating risk.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Multiagonists Outpace Older GLP-1 Drugs for Weight Loss
2
Vutrisiran Effects Consistent With, Without Tafamidis in ATTR-CM
3
Cardiac Risks of COVID-19 Vaccine vs Infection: Eman Toraih, MD, PhD
4
The Next Frontier in Hepatitis B Functional and Virologic Cure
5